cantharidin

Trade name: Ycanth

Small moleculeapproved

Approved

Jul 21, 2023

Cantharidin is a toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). Cantharidin is a medication used to remove warts and a viral skin infection called molluscum contagiosum. It is made from the secretions that come from the green blister beetle in combination with salicylic acid. It works by creating a blister just below the wart, which pushes the wart up and away from the underlying tissue, cutting of the blood supply to the wart. As the blister and the wart dry out, they both slough off, leaving fresh, unmarred skin behind. It is also used as an experimental anti-tumor agent. Several studies also show potential novel applications of cantharidin in acquired perforating dermatosis, acute herpes zoster, and leishmaniasis. In 1962, cantharidin lost Food and Drug Administration (FDA) approval owing to the failure of its manufacturers to submit data attesting to cantharidin's efficacy. However, in 1999, the FDA included cantharidin on its “Bulk Substances List” of drugs which although not available as commercial products, were approved for compounding on a customized basis for individual patients. — NCATS

Clinical trial activity

20 trials · 27 clinical orgs · 1 marketing orgs

Phase 1
7
Phase 2
8
Phase 3
4
Phase 4
2

Earliest trial started Jun 15, 2006 (NCT03625960)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Verrica Pharmaceuticals Inc. — Earliest Phase 3 Sponsor(trial)

2020s

  1. Jul 21, 2023

    Verrica Pharmaceuticals Inc. — Earliest FDA Approval

  2. Jul 21, 2023

    Verrica Pharmaceuticals Inc. — Marketing Organization

  3. Jul 21, 2023

    Verrica Pharmaceuticals Inc. — NDA Secondary Org

  4. Jul 21, 2023

    Verrica Pharmaceuticals Inc. — NDA Organization

Indications

Mechanism of action

  • DNADEGRADER

    DNA degrader

Approval history

  • approvedJul 21, 2023

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O
Mol. weight
196.1999 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • cantharidin
  • cantharidin
  • cantharidin
  • vp-102

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07246590Phase 3Dec 31, 2025Canfield Scientific Inc., Medidata Solutions, Verrica Pharmaceuticals Inc.
NCT07309419Phase 2/Phase 3 (Phase 3)Dec 22, 2025Fudan University
NCT05597098Early Phase 1 (Phase 1)Dec 1, 2022University of London
NCT05070754Phase 4Oct 1, 2021Columbia University, Medical University of South Carolina
NCT03981822Phase 2Jun 27, 2019BioClinica, Inc., Indiana Clinical Trials Center, Instat services, Paidion Research, Inc, Verrica Pharmaceuticals Inc.
NCT04308889Early Phase 1 (Phase 1)Jul 2, 2018Harvard University, National Institute of General Medical Sciences (NIGMS)
NCT03487549Phase 2Mar 27, 2018BioClinica, Inc., Instat services, Paidion Research, Inc, Verrica Pharmaceuticals Inc., Wake Dermatology
NCT03377790Phase 3Mar 21, 2018Database Integrations, Instat services, Paidion Research, Inc, University of California, San Diego, Verrica Pharmaceuticals Inc.
NCT03426995Phase 1Mar 13, 2018GlaxoSmithKline
NCT03377803Phase 3Feb 14, 2018Database Integrations, Instat services, Paidion Research, Inc, University of California, San Diego, Verrica Pharmaceuticals Inc.
NCT03306589Phase 1Aug 11, 2017GlaxoSmithKline
NCT03186378Phase 2Jun 8, 2017Cato Research, Instat services, Paidion Research, Inc, Verrica Pharmaceuticals Inc.
NCT03017846Phase 2Sep 1, 2016Yeshiva University
NCT02665260Phase 2Jul 1, 2012Yeshiva University
NCT01582321Early Phase 1 (Phase 1)Mar 1, 2012University of London
NCT01762787Phase 1Aug 17, 2010GlaxoSmithKline
NCT01026064Phase 1Jun 1, 2009GlaxoSmithKline
NCT00667225N/AJan 1, 2008Doris Duke Charitable Foundation, National Center for Research Resources (NCRR), University of North Carolina at Chapel Hill
NCT01084824N/AJun 1, 2007North Idaho Dermatology, Trident University
NCT03625960Phase 4Jun 15, 2006St. Vincents Hospital Manhattan, University of California, San Francisco, Wayne State University
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (27)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Verrica Pharmaceuticals Inc.For profit6622017
Instat servicesFor profit5022017
Paidion Research, IncFor profit5022017
GlaxoSmithKlineFor profit4412009
BioClinica, Inc.For profit2012018
Database IntegrationsFor profit2012018
University of California, San DiegoAcademic/Hospital2012018
University of LondonAcademic/Hospital2212012
Yeshiva UniversityAcademic/Hospital2212012
Canfield Scientific Inc.For profit1012025
Cato ResearchFor profit1012017
Columbia UniversityAcademic/Hospital1012021
Doris Duke Charitable FoundationAcademic/Hospital1012008
Fudan UniversityAcademic/Hospital1112025
Harvard UniversityAcademic/Hospital1112018
Indiana Clinical Trials CenterAcademic/Hospital1012019
Medical University of South CarolinaAcademic/Hospital1112021
Medidata SolutionsFor profit1012025
National Center for Research Resources (NCRR)Government1012008
National Institute of General Medical Sciences (NIGMS)Government1012018
27 organizations
Page 1 / 2

Marketing (3)

OrganizationOrg typeRelationshipDate
Verrica Pharmaceuticals Inc.For profitMKTGJul 21, 2023
Verrica Pharmaceuticals Inc.For profitNDA2Jul 21, 2023
Verrica Pharmaceuticals Inc.For profitNDAJul 21, 2023